Clinical Trial Update: Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial of memantine for prevention of cognitive dysfunction and negative symptoms in acute schizophrenia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: M. Schaefer, MD | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED